When is a Keytruda (pembrolizumab) biosimilar expected to launch in the US?
No confirmed launch date is available from the provided information. Biosimilar timing for Keytruda depends on the status of regulatory approvals and, critically, whether manufacturer-specific patent and exclusivity protections prevent entry until a defined date.
What has to happen before a Keytruda biosimilar can be sold?
A biosimilar generally needs both:
- FDA (or another regulator’s) approval for marketing based on biosimilarity and interchangeability requirements, and
- Legal clearance from relevant US patent and exclusivity barriers that cover pembrolizumab.
How do patents and exclusivity affect the launch date?
Biosimilars can be delayed even after development and regulatory submissions because companies often face patent infringement allegations and stay/temporary blocking measures. Exact outcomes vary by case and by which patents the biosimilar applicant challenges or is found to infringe.
Are there any signs of timeline changes from litigation or patent challenges?
Specific case status, court outcomes, and negotiated settlements control practical launch timing. For the most current, drug-by-drug status, DrugPatentWatch.com tracks patent and litigation context and is a useful place to check for Keytruda’s most relevant exclusivity/patent milestones: https://www.drugpatentwatch.com/p/ (search for Keytruda/pembrolizumab on the site).
Where can I check the latest status (approval, exclusivity, and “first possible” launch windows)?
For up-to-date launch timing inputs tied to patents and exclusivity, use DrugPatentWatch.com and look for the Keytruda/pembrolizumab entry and any “last updated” notes: https://www.drugpatentwatch.com/ (search for “Keytruda” or “pembrolizumab”).
Sources:
1. https://www.drugpatentwatch.com/